Literature DB >> 8707734

In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993.

O Scheel1, D J Lyon, V T Rosdahl, F A Adeyemi-Doro, T K Ling, A F Cheng.   

Abstract

MICs for 423 strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated in Hong Kong during 1988-1993 were performed for 15 antimicrobial agents: erythromycin, chloramphenicol, tetracycline, minocycline, gentamicin, netilmicin, trimethoprim, rifampicin, fusidic acid, ciprofloxacin, vancomycin, teicoplanin, sparfloxacin, clinafloxacin and RP 59500 (quinupristin/dalfopristin). Susceptibility to antibiotics generally remained stable throughout the study period, with the exception of the quinolones. Resistance to ciprofloxacin (breakpoint 4 mg/L) increased from a low of 9% in 1988 to a high of 82% in 1993. For sparfloxacin the corresponding figures were 9% and 78%, respectively. Six (1%) clinafloxacin-resistant strains were found. MIC50s and MIC90s of clinafloxacin increased from < or = 0.06 mg/L and 0.25 mg/L in 1988 to 1.0 mg/L and 2.0 mg/L, respectively, in 1993. All 423 strains were phage typed (typability 70%) and a diversity of phage types which changed during the observation period, with 13 dominating types, was observed. Ciprofloxacin resistance occurred in 12 of the dominating types, in 46 non-typable strains, and also in 23 strains of different, sporadically occurring types, indicating that the emergence of quinolone resistance was not due to dissemination of a single or few MRSA clones. The usefulness of quinolones in the treatment of MRSA infections is likely to be seriously constrained by the emergence of resistance. MICs for RP-59500 were < or = 2 mg/L for all isolates, suggesting that this agent merits further evaluation as an anti-MRSA agent. All MRSA remained susceptible to vancomycin and teicoplanin throughout the study period.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707734     DOI: 10.1093/jac/37.2.243

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Characterization of isolates of methicillin-resistant Staphylococcus aureus from Hong Kong by phage typing, pulsed-field gel electrophoresis, and fluorescent amplified-fragment length polymorphism analysis.

Authors:  M Ip; D J Lyon; F Chio; M C Enright; A F Cheng
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics.

Authors:  J Vouillamoz; J M Entenza; C Féger; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  Antagonism between aminoglycosides and beta-lactams in a methicillin-resistant Staphylococcus aureus isolate involves induction of an aminoglycoside-modifying enzyme.

Authors:  Takashi Ida; Ryoichi Okamoto; Masato Nonoyama; Kazuhiko Irinoda; Mizuyo Kurazono; Matsuhisa Inoue
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.

Authors:  Mahesh V Patel; Noel J De Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 5.  Nanofibers offer alternative ways to the treatment of skin infections.

Authors:  T D J Heunis; L M T Dicks
Journal:  J Biomed Biotechnol       Date:  2010-07-28

6.  Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.

Authors:  Y S Kim; Q Liu; L L Chow; H F Chambers; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

7.  Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.

Authors:  K J Christiansen; J M Bell; J D Turnidge; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.